Edition:
United States

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

1.65USD
1:57pm EST
Change (% chg)

$-0.06 (-3.78%)
Prev Close
$1.72
Open
$1.74
Day's High
$1.77
Day's Low
$1.64
Volume
47,644
Avg. Vol
147,415
52-wk High
$5.50
52-wk Low
$1.08

Latest Key Developments (Source: Significant Developments)

Catabasis Pharmaceuticals reports third quarter financial results
Thursday, 9 Nov 2017 04:10pm EST 

Nov 9 (Reuters) - Catabasis Pharmaceuticals Inc :Catabasis Pharmaceuticals reports third quarter 2017 financial results and reviews business progress.Q3 loss per share $0.31.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.Catabasis Pharmaceuticals Inc - co's current operating plan provides for cash to fund operations through august 2018​.  Full Article

Catabasis Pharmaceuticals reports positive DMD drug data
Wednesday, 4 Oct 2017 04:30am EDT 

Oct 4 (Reuters) - Catabasis Pharmaceuticals Inc ::Catabasis Pharmaceuticals reports positive results from open-­label extension of phase 2 MoveDMD trial evaluating edasalonexent in duchenne muscular dystrophy.Catabasis Pharmaceuticals says edasalonexent substantially slowed duchenne muscular dystrophy disease progression through 36 weeks in phase 2 trial.Plans to initiate single global phase 3 trial with edasalonexent in patients with DMD regardless of mutation type in first half of 2018.Catabasis Pharmaceuticals says top-­line results from single global phase 3 trial with edasalonexent expected in 2020.Catabasis Pharmaceuticals says edasalonexent continued to be well tolerated with no safety signals observed to date in movedmd trial.  Full Article

Catabasis Pharmaceuticals reports positive results from phase 2 trial of medicine for progressive muscle degeneration disease
Wednesday, 4 Oct 2017 04:30am EDT 

Oct 4 (Reuters) - Catabasis Pharmaceuticals Inc : :Catabasis Pharmaceuticals reports positive results from open-label extension of phase 2 movedmd® trial evaluating Edasalonexent in duchenne muscular dystrophy and plans to initiate phase 3 clinical trial in first half 2018.Catabasis Pharmaceuticals Inc - ‍Edasalonexent substantially slowed duchenne muscular dystrophy disease progression through 36 weeks​.Catabasis - ‍plans to initiate a single global phase 3 trial with Edasalonexent in patients with DMD regardless of mutation type in first half of 2018​.Catabasis Pharmaceuticals Inc - ‍expects to report top-line results from single global phase 3 trial in DMD in 2020​.Catabasis Pharmaceuticals Inc - ‍heart rate of boys with DMD treated with Edasalonexent decreased toward "age-normative values" during treatment​.Catabasis - ‍believe clinical heart rate observations in boys with DMD treated with Edasalonexent​ "are intriguing and warrant follow-up".  Full Article

Catabasis Pharmaceuticals Q2 loss per share $0.32
Thursday, 10 Aug 2017 04:10pm EDT 

Aug 10 (Reuters) - Catabasis Pharmaceuticals Inc :Catabasis Pharmaceuticals reports second quarter 2017 financial results and reviews business progress.Q2 loss per share $0.32.Q2 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S.Catabasis Pharmaceuticals Inc - ‍continue to advance open-label extension and expect to share 24-week edasalonexent results in Q3.Catabasis Pharmaceuticals Inc - ‍phase 3 clinical trial plan for edasalonexent in second half of 2017​.Catabasis Pharmaceuticals Inc - ‍as of June 30, cash and cash equivalents of $29.4 million, versus $31.8 million last quarter.Catabasis Pharmaceuticals Inc - ‍Catabasis expects that its current operating plan provides for cash to fund operations through August, 2018​.  Full Article

Catabasis Pharmaceuticals Q1 loss per share $0.41
Thursday, 11 May 2017 04:10pm EDT 

May 11 (Reuters) - Catabasis Pharmaceuticals Inc :Catabasis pharmaceuticals reports first quarter 2017 financial results and reviews business progress.Q1 loss per share $0.41.Q1 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.  Full Article

Catabasis Pharmaceuticals announces favorable results for functional assessments in the MoveDMD trial for edasalonexent
Tuesday, 25 Apr 2017 08:00am EDT 

April 25 (Reuters) - Catabasis Pharmaceuticals Inc :Catabasis Pharmaceuticals announces favorable results for functional assessments in the MoveDMD trial for edasalonexent in duchenne muscular dystrophy at the American Academy of Neurology 69th annual meeting.Catabasis Pharmaceuticals Inc - Part C interim results to be announced in Q3 2017 for MoveDMD trial for edasalonexent.Catabasis Pharmaceuticals - prespecified analysis of Part B data from MoveDMD trial shows improvement in rates of change across 5 functional assessments.Catabasis Pharmaceuticals Inc - consistent with Part A, there were no safety signals and edasalonexent was well tolerated in Part B of trial.Catabasis Pharmaceuticals - there were no treatment-related serious adverse events, no drug discontinuations and no dose reductions in Part B of trial.  Full Article

Catabasis Pharma Q4 loss per share $0.47
Thursday, 16 Mar 2017 04:10pm EDT 

Catabasis Pharmaceuticals Inc : Catabasis pharmaceuticals reports fourth quarter and full year 2016 financial results and recent corporate highlights . Q4 loss per share $0.47 .Q4 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.  Full Article

James Flynn reports 4.21 pct passive stake in Catabasis Pharma - SEC filing
Friday, 30 Sep 2016 06:23am EDT 

:James Flynn reports 4.21 percent passive stake in Catabasis Pharmaceuticals Inc as of September 28 - SEC filing.  Full Article

Catabasis Pharma & Sarepta Therapeutics to collaborate in Duchenne muscular dystrophy
Thursday, 29 Sep 2016 08:00am EDT 

Catabasis Pharmaceuticals Inc : Collaboration to study exon skipping treatment by Sarepta with co's oral NF-KB inhibition treatment in mouse model of DMD . Catabasis Pharmaceuticals and Sarepta Therapeutics announce a joint research collaboration in Duchenne muscular dystrophy .Collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy.  Full Article

Catabasis announces pricing of an underwritten offering of 2.5 mln shares
Friday, 23 Sep 2016 07:00am EDT 

Catabasis Pharmaceuticals Inc [CATB.O] : Catabasis Pharmaceuticals announces pricing of $10 million offering of common stock .Catabasis Pharmaceuticals Inc says pricing of an underwritten offering of 2.5 million shares of its common stock at a price of $4.00 per share.  Full Article

BRIEF-Catabasis Pharmaceuticals reports third quarter financial results

* Catabasis Pharmaceuticals reports third quarter 2017 financial results and reviews business progress